A Clinical Comparative Study of Piperacillin and Sulbactam/Ampicillin in Patients with Community-Acquired Bacterial Pneumonia

被引:5
作者
Seki, Masafumi [1 ,2 ]
Higashiyama, Yasuhito [2 ,4 ]
Imamura, Yoshifumi [1 ,2 ]
Nakamura, Shigeki [1 ,2 ]
Kurihara, Shintaro [2 ]
Izumikawa, Koichi [1 ,2 ]
Kakeya, Hiroshi [1 ,2 ]
Yamamoto, Yoshihiro [1 ,2 ]
Yanagihara, Katsunori [3 ]
Tashiro, Takayoshi [1 ,2 ]
Kohno, Shigeru [1 ,2 ]
机构
[1] Nagasaki Univ, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, Nagasaki 852, Japan
[2] Nagasaki Univ, Sch Med, Dept Internal Med 2, Nagasaki 852, Japan
[3] Nagasaki Univ, Sch Med, Dept Lab Med, Nagasaki 852, Japan
[4] Hokusho Chuo Hosp, Nagasaki, Japan
关键词
community-acquired pneumonia; antibiotics; clinical trials; pulmonary infections; METALLO-BETA-LACTAMASE; ETIOLOGY;
D O I
10.2169/internalmedicine.48.1614
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate the clinical usefulness of piperacillin (4 g/day) therapy for community-acquired pneumonia compared to sulbactam/ ampicillin (6 g/day). Methods A randomized prospective clinical study was conducted in patients with mild to severe community-acquired bacterial pneumonia. Results The overall clinical efficiency of piperacillin therapy (4 g/day) in these patients (41/53=77.4%) was comparable to that of sulbactam/ ampicillin therapy (6 g/day: efficiency rate: 33/49= 67.3%), when each therapy was administered intravenously for 3-7 days. With regards to clinical efficiency based on disease severity, bacteriological efficiency, improvement in chest X-ray findings and adverse reactions, the two therapies were comparable, even though we found more efficiency for patients who had underlying diseases and there were also cost benefits in piperacillin therapy, compared with sulbactam/ampicillin therapy Conclusion The results suggested that piperacillin therapy has good efficiency and tolerability and that it may be highly effective, even in cases of pneumonia with underlying diseases. This regimen may thus serve as a first line treatment of community-acquired pneumonia.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 23 条
[21]   Interventions to prevent pneumonia among older adults [J].
Yamaya, M ;
Yanai, M ;
Ohrui, T ;
Arai, H ;
Sasaki, H .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (01) :85-90
[22]   Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia [J].
Yanagihara, Katsunori ;
Fukuda, Yuichi ;
Seki, Masafumi ;
Izumikawa, Koichi ;
Higashiyama, Yasuhito ;
Miyazaki, Yoshitsugu ;
Hirakata, Yoichi ;
Tomono, Kazunori ;
Mizuta, Yohei ;
Tsukamoto, Kazuhiro ;
Kohno, Shigeru .
INTERNAL MEDICINE, 2006, 45 (17) :995-999
[23]  
2006, RESPIROLOGY, V11, pS79